Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Block Listing Six Monthly Return

2 Jan 2019 07:00

RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com

MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE
Date   Source Headline
16th Nov 20167:00 amRNSResearch Update from Modus Therapeutics
15th Nov 20164:33 pmRNSHolding(s) in Company
1st Nov 20167:00 amRNSCo-Development Agreement with Asarina AB
24th Oct 20167:00 amRNSErgomed notes news from co-development partner
14th Oct 20167:00 amRNSFourth licensing agreement for Zoptrex
26th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSContract win validates rationale of acquisitions
16th Sep 201610:56 amRNSErgomed receives a "buy" recommendation
8th Sep 20167:00 amRNSRecruitment completed in phase IIa clinical trial
7th Sep 201611:30 amRNSNotice of Results
2nd Sep 20167:00 amRNSCo-development partner announces licensing deals
15th Aug 20167:01 amRNSChange of Nominated Adviser
15th Aug 20167:00 amRNSDisclosure of Directors' Appointments
27th Jun 20161:55 pmRNSResult of AGM
27th Jun 20167:00 amRNSUS expansion and opening of office in Boston
20th Jun 20165:49 pmRNSNotice of AGM
14th Jun 201611:49 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAcquisition
6th Jun 20163:31 pmRNSHolding(s) in Company
31st May 20164:45 pmRNSTotal Voting Rights
25th May 201611:55 amRNSHolding(s) in Company
23rd May 201611:10 amRNSResult of Meeting
16th May 20167:00 amRNSPlacing Update
4th May 201612:30 pmRNSProposed acquisition of Haemostatix Limited
30th Mar 201612:00 pmRNSNotice of Results
1st Feb 20161:42 pmRNSHolding(s) in Company
1st Feb 20167:00 amRNSTrading Statement
11th Jan 20167:02 amRNSErgomed Award of Share Options to Director
11th Jan 20167:00 amRNSErgomed announces Board changes
24th Dec 20157:00 amRNSErgomed Awards Share Options
17th Dec 20157:00 amRNSHolding(s) in Company
16th Dec 20157:00 amRNSErgomed Update on Co-Development Partnerships
5th Nov 20157:00 amRNSHolding(s) in Company
29th Oct 201510:00 amRNSErgomed plc to present at German Equity Forum 2015
21st Oct 20159:21 amRNSErgomed Co-Development Partner News
14th Oct 20157:00 amRNSErgomed's Co-Development Partner News
13th Oct 20157:00 amRNSErgomed and Dilaforette Initiate Phase II
5th Oct 20151:09 pmRNSErgomed expands co-development with CEL-SCI
29th Sep 20157:01 amRNSErgomed Interim Results 2015
23rd Sep 20158:00 amRNSErgomed shortlisted for Leading Industry Award
15th Sep 20157:00 amRNSNotice of Results
14th Aug 20157:00 amRNSCo-development partner news
21st Jul 20152:30 pmRNSHolding(s) in Company
20th Jul 20154:20 pmRNSSecondary Placing Of Ordinary Shares in Ergomed
14th Jul 20159:56 amRNSCo-development partner news
10th Jul 20157:00 amRNSAppointment of Director - additional information
2nd Jul 20157:00 amRNSErgomed Strengthens Management Team & Board
30th Jun 201512:43 pmRNSCo-development partner news
25th Jun 20151:06 pmRNSCo-development partner news
19th Jun 201512:35 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.